Jean-Frederic Colombel
Icahn School of Medicine at Mount Sinai
Internal medicineSurgeryPathologyIntensive care medicineImmunologyPlaceboColitisVedolizumabInfliximabInflammatory bowel diseaseDiseaseCrohn's diseaseAdalimumabUlcerative colitisPopulationIn patientClinical trialMedicineBiologyGastroenterology
1,396Publications
169H-index
87.6kCitations
Publications 1,400
Newest
#1Silvio Danese (UniSR: Vita-Salute San Raffaele University)H-Index: 2
#2Jean-Frederic Colombel (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 169
Last. Christopher ZiadyH-Index: 1
view all 247 authors...
Summary null null Background null Etrolizumab is a gut-targeted anti-β7 integrin monoclonal antibody. In a previous phase 2 induction study, etrolizumab significantly improved clinical remission versus placebo in patients with moderately to severely active ulcerative colitis. We aimed to compare the safety and efficacy of etrolizumab with infliximab in patients with moderately to severely active ulcerative colitis. null null null Methods null We conducted a randomised, double-blind, double-dummy...
Source
#1Antonio Fabio Di Narzo (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 22
#2Sander M. Houten (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 62
Last. Carmen Argmann (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 35
view all 29 authors...
Abstract null Background null Polygenic and environmental factors are underlying causes of inflammatory bowel disease (IBD). We hypothesized that integration of the genetic loci controlling a metabolite's abundance, with known IBD genetic susceptibility loci, may help resolve metabolic drivers of IBD. null Methods null We measured the levels of 1300 metabolites in the serum of 484 ulcerative colitis (UC) and 464 Crohn's disease (CD) patients and 365 controls. Differential metabolite abundance wa...
Source
#1John Sperger (UNC: University of North Carolina at Chapel Hill)H-Index: 1
#2Kushal S. Shah (UNC: University of North Carolina at Chapel Hill)H-Index: 2
Last. Michael R. Kosorok (UNC: University of North Carolina at Chapel Hill)H-Index: 58
view all 10 authors...
Objectives null Develop an individualised prognostic risk prediction tool for predicting the probability of adverse COVID-19 outcomes in patients with inflammatory bowel disease (IBD). null Design and setting null This study developed and validated prognostic penalised logistic regression models using reports to the international Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease voluntary registry from March to October 2020. Model development was do...
Source
#1Walter Reinisch (Medical University of Vienna)H-Index: 104
#2Stanley N. CohenH-Index: 132
Last. Jean-Frederic Colombel (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 169
view all 8 authors...
ABP 710 (AVSOLA®) is a biosimilar to infliximab reference product (RP), a monoclonal antibody targeting tumor necrosis factor alpha (TNFα). It is approved in the USA and Canada for all the same indications as infliximab RP. Approval of ABP 710 was based on the totality of evidence (TOE) generated using a stepwise approach to assess its similarity with infliximab RP with regard to analytical (structural and functional) characteristics, pharmacokinetic parameters, and clinical efficacy and safety....
Source
#1Shomron Ben-Horin (Sheba Medical Center)H-Index: 58
#2Lena Novack (BGU: Ben-Gurion University of the Negev)H-Index: 25
Last. Minhu ChenH-Index: 56
view all 14 authors...
Background and Aims null Starting biologic treatment early in the course of inflammatory bowel disease (IBD) may be associated with higher efficacy, especially in Crohn's disease (CD). null Methods null This was a systematic review and individual-patient data meta-analysis of all placebo-controlled trials of biologics approved for IBD at study inception (October 2015), using Vivli data-sharing platform. The primary outcome was the proportional biologic/placebo treatment effect on induction of re...
Source
#2Jean-Frederic Colombel (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 169
Last. Jean-François RahierH-Index: 28
view all 26 authors...
Background and aims null Few data are available regarding the combination of biologics or small molecules in inflammatory bowel disease (IBD) patients. We report safety and efficacy of such combinations through a retrospective multicentre series. null Methods null Combination therapy was defined as the concomitant use of two biologics or one biologic with a small molecule. Patient demographics, disease characteristics and types of combinations were recorded. Safety was evaluated according to the...
Source
#1Neeraj Narula (McMaster University)H-Index: 25
#2Emily C L Wong (McMaster University)H-Index: 3
Last. Parambir S. Dulai (UCSD: University of California, San Diego)H-Index: 32
view all 8 authors...
BACKGROUND AND AIMS This study evaluated the minimal clinically important short-term improvement in the MM-SES-CD, a novel modified scoring system of the SES-CD, that reliably predicted one-year ER. METHODS This post-hoc analysis of two CD clinical trial programs pooled data of 198 participants with baseline ulcers and SES-CD ≥3 who had baseline, post-induction (8-12 weeks), and one-year endoscopic assessments. Different cutoff values for endoscopic response were evaluated using receiver operati...
Source
#1Judith Wellens (Katholieke Universiteit Leuven)H-Index: 2
#2Matthew Edmans (John Radcliffe Hospital)H-Index: 9
Last. Craig Thompson (University of Oxford)H-Index: 15
view all 16 authors...
There is substantial interest regarding the perceived risk that immunomodulator and biologic therapy could have on COVID-19 disease severity among patients with inflammatory bowel disease (IBD) and clinicians. In this study, we show that infliximab/thiopurine combination therapy is associated with significantly lower IgA, a range of lower IgG responses as well as impaired neutralising antibody responses, compared to responses observed in healthy individuals. We also demonstrate that whilst IgG r...
Source
#1Neeraj Narula (McMaster University)H-Index: 25
#2Emily C L Wong (McMaster University)H-Index: 3
Last. Walter Reinisch (Medical University of Vienna)H-Index: 104
view all 6 authors...
BACKGROUND AND AIMS There is paucity of evidence on the reversibility of Crohn's disease (CD) related strictures treated with therapies. We aimed to describe the clinical and endoscopic outcomes of CD patients with non-passable strictures. METHODS This was a post-hoc analysis of three large CD clinical trial programs examining outcomes with infliximab, ustekinumab, and azathioprine, which included data on 576 patients including 105 with non-passable strictures and 45 with passable strictures, as...
Source
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.